International Journal of Glaucoma

The Open Access Pub has the reputation for quick reviewing and publishing original research articles. The editorial boards of our journals have many dedicated and reputed scientists as editorial members. Their support helps many researchers from all countries to enhance their research between scientists of various communities. This platform plays a crucial role in promoting science networks and exchanges.

International Journal of Glaucoma-Glaucoma disease mechanism-Iok-Hou Pang

United States

Pharmaceutical Sciences,
North Texas Eye Research Institute,
University of North Texas Health Science Center.

817-735-2960

Send an Email

Iok-Hou Pang

Address:

3500 Camp Bowie Blvd,
Fort Worth, TX 76107.

Research Interests:

  • Glaucoma disease mechanism
  • Glaucoma neuroprotection
  • Glaucomatous retinopathy
  • Glaucomatous optic neuropathy

Biography:

  • Dr. Iok-Hou Pang has been involved in glaucoma drug discovery at Alcon Laboratories, Fort Worth, Texas, for more than 20 years, and became the Head of Glaucoma Research since 2008.
  • In 2012, he joined the Health Science Center as professor and chair of Pharmaceutical Sciences in the newly established College of Pharmacy, and is a member of the North Texas Eye Research Institute.
  • Dr. Pang is also an adjunct faculty member of the Biomedical Engineering Graduate Program at the University of Texas at Arlington, a visiting professor of the School of Pharmacy, National Defense Medical Center in Taipei; Shanxi Eye Hospital in Taiyuan, China; Sichuan University in Chengdu, China; and Shenzhen Eye Hospital of Jinan University in Shenzhen, China.
  • Dr. Pang has edited one book, published more than 90 peer-reviewed manuscripts and book chapters, and has been issued numerous U.S. and international patents.
  • He is an editor of "Medicine" and reviewers of various ophthalmology and pharmacology journals.
  • Dr. Pang's research interests mainly focus on the understanding of glaucoma etiology, pathology, and pharmacology, especially on glaucoma neuroprotection.
  • He is working to delineate essential molecular and cellular mechanisms, as well as characterize receptors and signal transduction pathways related to the abnormal changes in glaucoma.
  • His laboratory is using rodent and primary cultures of retinal cells as study models to clarify biological events leading to glaucomatous retinopathy and optic neuropathy, as well as its prevention and protection.